LOGIN  |  REGISTER
Cue Biopharma

Neuronetics Releases Software Upgrades to Elevate Patient Care

September 16, 2024 | Last Trade: US$0.94 0.0071 -0.75

TOPLINE SUMMARY

• Neuronetics, Inc. has announced enhancements to its NeuroStar Advanced Therapy and proprietary TrakStar patient data management software.
• The upgrades introduce a range of new features aimed at improving patient communication, streamlining clinical data capture, and strengthening cybersecurity.
• The new features in the NeuroStar System and TrakStar are designed to empower providers with the tools they need to deliver more personalized, efficient, and secure treatment.
• The software updates provide practices with more robust tools to better manage patient needs on a local scale.
• Practices can now access a wider range of automated patient clinical surveys to monitor well-being during and after treatment.
• Advanced Clinical Data Capture: NeuroStar’s internet-connected device now synchronizes critical clinical information with the TrakStar data management.
• The upgrades aim to empower providers with the tools they need to deliver more personalized.
• This will enable additional real-time insights to provide more effective, tailored care.

MALVERN, Pa., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced enhancements to its NeuroStar Advanced Therapy and proprietary TrakStar® patient data management software, introducing a range of new features aimed at improving patient communication, streamlining clinical data capture, and strengthening cybersecurity.

“With the latest upgrades, we’re not just enhancing technology; we’re transforming the way practices can care for patients,” said Cory Anderson, SVP of R&D and Clinical. “The new features in the NeuroStar System and TrakStar are designed to empower providers with the tools they need to deliver more personalized, efficient, and secure treatment. Our commitment is to continually push the boundaries of what our technology can do, ensuring that NeuroStar remains at the forefront of advancing the way patients receive treatment in their battle against depression.”

The software updates provide practices with more robust tools to enhance patient care and streamline operations for NeuroStar practices. Key upgrades include:

  • Enhanced Patient Communication: New CRM capabilities automate SMS and email communication, offering personalized guidance during the early stages of NeuroStar treatment. Secure insurance card uploads now streamline claims processing and reduce errors from manual entries. Additionally, multi-site practices can filter communications by location to better manage patient needs on a local scale.
  • Expanded TrakStar Survey Options: Practices can now access a wider range of automated patient clinical surveys to monitor well-being during and after treatment, enabling additional real-time insights to provide more effective, tailored care.
  • Advanced Clinical Data Capture: NeuroStar’s internet-connected device now synchronizes critical clinical information with the TrakStar data management system, securely automating tracking and enhancing data collection accuracy.
  • Improved Security: Proactive updates to the Operating System are part of NeuroStar’s strong commitment to ensuring safe, secure, and encrypted patient data and digital communications.

TrakStar software updates are available today for all cloud-based NeuroStar providers. NeuroStar System software updates are being delivered in a phased rollout throughout the year. For more information about NeuroStar TMS Therapy, please visit www.neurostar.com.

About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. NeuroStar is indicated for the treatment of depressive episodes and for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from MDD and who failed to achieve satisfactory improvement from previous antidepressant medication treatment in the current episode. It is also FDA-cleared as an adjunct for adults with obsessive-compulsive disorder and for adolescent patients aged 15-21 with MDD. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with over 6.6 million treatments delivered. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, visit www.neurostar.com.

Media Contact:
EvolveMKD
646.517.4220
This email address is being protected from spambots. You need JavaScript enabled to view it.

C4 Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB